Related Experiment Video

Updated: Jun 1, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Myeloperoxidase gene-463G > A polymorphism and premature coronary artery disease

Chen Zhong1, Yin Quanzhong, Ma Genshan

  • 1Department of Cardiology, The Affiliated ZhongDa Hospital of Southeast University, Nanjing P.R. China.

Genetics and Molecular Biology
|June 4, 2011
PubMed

Insights

The myeloperoxidase (MPO) gene -463G > A polymorphism, specifically the AA genotype, is linked to a reduced risk of premature coronary artery disease (CAD) in Chinese populations. This finding suggests a protective role for the AA genotype against early-onset CAD.

Area of Science:

  • Genetics
  • Cardiovascular Medicine
  • Molecular Biology

Background:

  • Premature coronary artery disease (CAD) poses a significant global health challenge.
  • Genetic factors play a crucial role in the development of premature CAD.
  • The myeloperoxidase (MPO) gene is implicated in inflammatory processes relevant to atherosclerosis.

Purpose of the Study:

  • To investigate the association between the myeloperoxidase (MPO) gene -463G > A polymorphism and premature CAD in a Chinese population.
  • To determine if specific genotypes of the MPO -463G > A polymorphism confer differential risk for premature CAD.

Main Methods:

  • Case-control study design involving 229 premature CAD patients and 230 healthy controls from Chinese populations.
  • Genotyping of the MPO -463G > A polymorphism using ligase detection reaction-polymerase chain reaction sequencing.
  • Statistical analysis including logistic regression to assess the association between genotypes and premature CAD risk.

Main Results:

  • Lower frequencies of the A/A genotype and the A allele were observed in patients with premature CAD compared to controls (p < 0.05).
  • Multivariate logistic regression analysis revealed that individuals with the AA genotype had a significantly reduced risk of premature CAD (OR = 0.172, 95% CI: 0.057-0.526, p = 0.002).
  • The AA genotype was associated with an 83% reduction in premature CAD risk relative to the G/G genotype.

Conclusions:

  • The myeloperoxidase (MPO) gene -463G > A polymorphism is significantly associated with premature coronary artery disease in the studied Chinese population.
  • The AA genotype of the MPO -463G > A polymorphism appears to be a protective factor against the development of premature CAD.
  • These findings highlight the potential role of MPO genetics in cardiovascular disease risk stratification.

Keywords:
premature coronary artery diseasemyeloperoxidaseprotective genetic polymorphism

More Related Videos

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...